ARRIVENT BIOPHARMA INC. - COMMON STOCK

ArriVent BioPharma Reports Full Year 2024 Financial Results

03 3 2025 07:00:00 提供 Nasdaq GlobeNewswire

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

21 1 2025 19:00:00 提供 Nasdaq GlobeNewswire

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

14 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

09 9 2024 12:05:00 提供 Nasdaq GlobeNewswire

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

14 8 2024 16:01:00 提供 Nasdaq GlobeNewswire

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

12 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

05 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

16 5 2024 16:05:00 提供 Nasdaq GlobeNewswire